Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals, Inc. (CTXR) Healthcare & Pipeline Overview

Citius Pharmaceuticals, Inc. develops and commercializes critical care pharmaceuticals, focusing on anti-infective and cancer care products. Their pipeline includes Mino-Lok for catheter-related infections, Mino-Wrap for post-surgery infections, and NoveCite for acute respiratory distress syndrome, positioning them in a competitive biotechnology market.

What Is the Investment Thesis for CTXR?

Citius Pharmaceuticals presents a speculative investment opportunity driven by its pipeline of critical care products, particularly Mino-Lok, which is in late-stage development. Successful completion of clinical trials and subsequent FDA approval for Mino-Lok could drive significant revenue growth. The company's focus on addressing unmet needs in infection control and cancer care provides a clear market opportunity. However, the company's negative profit margin of -823.3% and reliance on future product approvals represent substantial risks. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure funding to support ongoing operations. The company's market capitalization of $6.66M reflects its early stage and inherent risks.

Based on FMP financials and quantitative analysis

CTXR Key Highlights

• Citius Pharmaceuticals is developing Mino-Lok, an antibiotic lock solution to treat catheter-related bloodstream infections.
• The company's pipeline includes Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries.
• Halo-Lido, a corticosteroid-lidocaine topical formulation, is being developed for hemorrhoid relief.
• NoveCite, a mesenchymal stem cell therapy, is in development for the treatment of acute respiratory disease syndrome.
• Citius Pharmaceuticals reported a gross margin of 37.4%.

Who Are CTXR's Competitors?

CTXR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTXR's Key Strengths?

• Pipeline of product candidates targeting unmet medical needs.
• Focus on critical care products with potential for market exclusivity.
• Proprietary drug formulations and intellectual property.
• Experienced management team with pharmaceutical development expertise.

What Are CTXR's Weaknesses?

• Negative profit margin and reliance on future product approvals.
• Limited financial resources and dependence on external funding.
• High risk associated with clinical trials and regulatory approvals.
• Small number of employees.

What Could Drive CTXR Stock Higher?

• Data readout from the Mino-Lok Phase 3 trial.
• FDA submission for Mino-Lok.
• Enrollment in clinical trials for Mino-Wrap.
• Development of NoveCite for ARDS treatment.

What Are the Key Risks for CTXR?

• Financial-distress signal — its Altman Z-Score of -4.39 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-67.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approval for Mino-Lok.
• Unfavorable clinical trial results for Mino-Wrap or NoveCite.
• Competition from established pharmaceutical companies.
• Dependence on external funding to support operations.

What Are the Growth Opportunities for CTXR?

• Mino-Lok Commercialization: The successful completion of Phase 3 trials and subsequent FDA approval of Mino-Lok for the treatment of catheter-related bloodstream infections (CRBSIs) represents a significant growth opportunity. The market for CRBSI treatment is substantial, with thousands of cases occurring annually. Mino-Lok's potential to salvage infected catheters could position it as a valuable alternative to catheter removal, driving adoption and revenue growth. The timeline for commercialization depends on regulatory approval, but could potentially occur within the next 2-3 years.
• Mino-Wrap Development and Approval: The development and approval of Mino-Wrap for reducing tissue expander infections following breast reconstructive surgeries presents another growth avenue. Post-operative infections are a common complication, and Mino-Wrap's liquifying gel-based wrap could offer a novel solution. Successful clinical trials and regulatory approval could lead to market penetration and revenue generation. The timeline for this product is dependent on clinical trial progress and regulatory pathways.
• NoveCite for ARDS Treatment: The development of NoveCite, a mesenchymal stem cell therapy for acute respiratory disease syndrome (ARDS), represents a high-potential growth opportunity. ARDS is a severe inflammatory lung condition with limited treatment options. If NoveCite demonstrates efficacy in clinical trials, it could address a significant unmet medical need and capture a substantial share of the ARDS treatment market. The timeline for NoveCite's development is subject to clinical trial outcomes and regulatory approvals.
• Halo-Lido for Hemorrhoid Relief: The commercialization of Halo-Lido, a corticosteroid-lidocaine topical formulation for hemorrhoid relief, offers a potential revenue stream. Hemorrhoids are a common condition, and Halo-Lido's anti-inflammatory and anesthetic properties could provide effective symptom relief. Successful clinical trials and regulatory approval could lead to market adoption and revenue generation. The timeline for this product depends on clinical trial progress and regulatory pathways.
• I/ONTAK for Cutaneous T-Cell Lymphoma: The development and potential approval of I/ONTAK for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) provides another growth opportunity. CTCL is a rare type of cancer, and I/ONTAK's targeted approach could offer a valuable treatment option. Successful clinical trials and regulatory approval could lead to market penetration and revenue generation. The timeline for I/ONTAK's development is subject to clinical trial outcomes and regulatory approvals.

What Opportunities Does CTXR Have?

• Successful completion of clinical trials and FDA approval for Mino-Lok.
• Expansion of product pipeline through strategic acquisitions or partnerships.
• Growing demand for innovative therapies in critical care.
• Potential for orphan drug designation and accelerated regulatory pathways.

What Threats Does CTXR Face?

• Failure to obtain regulatory approval for product candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Unfavorable clinical trial results.
• Changes in healthcare regulations and reimbursement policies.

What Are CTXR's Competitive Advantages?

• Proprietary drug formulations and intellectual property protection through patents.
• Specialized focus on critical care products and unmet medical needs.
• Pipeline of product candidates in various stages of development.
• Potential for market exclusivity upon regulatory approval of novel therapies.

What Does CTXR Do?

Founded in 2007 and headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative critical care products. The company's focus lies primarily in anti-infective products, adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Their lead product candidate is Mino-Lok, an antibiotic lock solution designed to treat patients with catheter-related bloodstream infections (CRBSIs) by salvaging the infected catheter, potentially reducing the need for catheter removal and replacement. In addition to Mino-Lok, Citius is developing Mino-Wrap, a liquifying gel-based wrap intended to reduce tissue expander infections following breast reconstructive surgeries. This product aims to address a significant unmet need in post-operative care. Halo-Lido, another product in development, is a corticosteroid-lidocaine topical formulation designed to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. NoveCite, a mesenchymal stem cell therapy, is being developed for the treatment of acute respiratory disease syndrome (ARDS), a severe inflammatory lung condition. Finally, I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein, is being developed for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Citius Pharmaceuticals operates within the highly competitive biotechnology industry, striving to bring novel solutions to critical care challenges. Their strategy involves a combination of in-house development and potential partnerships to advance their product pipeline and commercialize their therapies. The company's focus on addressing unmet medical needs in areas such as infection control and cancer care positions them for potential growth within the pharmaceutical market.

What Products and Services Does CTXR Offer?

• Develop and commercialize critical care pharmaceutical products.
• Focus on anti-infective products for catheter-related bloodstream infections.
• Develop therapies for adjunct cancer care.
• Create prescription products for various medical conditions.
• Research and develop mesenchymal stem cell therapies.
• Address unmet medical needs in infection control and cancer care.

How Does CTXR Make Money?

• Develop proprietary pharmaceutical products through in-house research and development.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Seek regulatory approval from agencies like the FDA to commercialize their products.
• Potentially partner with other pharmaceutical companies for manufacturing, distribution, and commercialization.

What Industry Does CTXR Operate In?

Citius Pharmaceuticals operates within the biotechnology industry, a sector characterized by high risk and high reward. The industry is driven by innovation and the development of new therapies for unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller, specialized biotechnology firms. Citius focuses on critical care products, positioning it within a niche market that addresses specific medical challenges. The biotechnology industry is subject to stringent regulatory requirements and lengthy clinical trial processes, which can significantly impact the timeline and cost of bringing new products to market. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by advancements in genomics, personalized medicine, and biopharmaceutical development.

Who Are CTXR's Key Customers?

• Hospitals and healthcare facilities that treat patients with catheter-related bloodstream infections.
• Surgeons and medical professionals performing breast reconstructive surgeries.
• Patients suffering from hemorrhoids.
• Patients with acute respiratory disease syndrome (ARDS).
• Oncologists and patients with cutaneous T-cell lymphoma.

Citius Pharmaceuticals, Inc. Financial Trajectory

Citius Pharmaceuticals, Inc. (CTXR) reported $1.7M in revenue for Q1 2026, a decline of 57.7% compared to the prior quarter. The company recorded a net loss of $21.2M, with diluted EPS of $-0.95.

Company Profile

Citius Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cranford, US. The company is led by CEO Leonard L. Mazur. CTXR has traded publicly since 2014.

How Citius Pharmaceuticals, Inc. Is Valued

Citius Pharmaceuticals, Inc. carries a market capitalization of $6.66M, placing it in the micro-cap category. Relative to its peer group, CTXR's quantitative score of 18/100 is below the peer average of 85/100.

ROE -67%Key Financial Metrics

Return on equity for Citius Pharmaceuticals, Inc. stands at -67.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.9%, showing how much profit it generates from its asset base. A current ratio of 0.58 means current liabilities exceed short-term assets, a liquidity point worth watching.

F-Score 3/9Financial Health

Citius Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.39 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Citius Pharmaceuticals, Inc. revenue of about $20.8M for fiscal 2026, with EPS near $-1.87.

CTXR Financials

CTXR Latest News

CTXR Analyst Consensus

CTXR MoonshotScore

Citius Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources